• November 7 (THU)
  • November 8 (FRI)
08:40-09:00 Opening Ceremony 10:00~18:30Poster Session
09:00-10:15 Scientific Symposium 1
Current status of precision medicine in oncology area
Scientific Symposium 2
IT biotech & digital health in oncology
Scientific Symposium 3
Immunotherapy: Emerging strategies for combination of immune checkpoint modulators
Scientific Symposium 4
State of the art on systemic therapy in HCC
10:15-10:30 Break
10:30-11:10 Plenary Lecture 1
Targeting DNA repair in Breast Cancer
Andrew Tutt
(The Institute of Cancer Research, UK)
11:10-11:50 Presidential Sympsoium
The VHL tumor suppressor gene: Insights into oxygen sensing and cancer
William G. Kaelin, Jr.
(Dana-Farber Cancer Institute, USA)
11:50-12:30 Luncheon Symposium 1

New Horizon of Neoadjuvant and Adjuvant Treatment in HER2-positive Breast Cancer
Luncheon Symposium 2

New perspectives for the future treatment option in non small cell lung cancer
Satellite Symposium 1

How can we improve the outcome of pancreatic cancer?
12:30-12:50 Break
12:50-13:50 Special Symposium
Research, write, publish
Presentation 1
Presentation 2
Multidisciplinary Oncology Team Education Session 1
Immuno-oncologic therapy and pharmacologic management KOR
Presentation 3
13:50-14:10 Break
14:10-15:40 ASCO/KSMO
Joint Symposium 1

Utilization of NGS to improve patient care
Scientific Symposium 5
Modulating microenvironment for cancer treatment
Joint Symposium

The promise of combining RT and immunotherapy
Multidisciplinary Oncology Team Education Session 2
Oncology nursing care in immune-oncology and targeted agent KOR
15:40-16:00 Break
16:00-17:30 ASCO/KSMO
Joint Symposium 2

Integrated platform for precision medicine
Scientific Symposium 6
Translational Research - Biomarker studies to achieve desired clinical applications
Scientific Symposium 7
GY cancer multimodality treatment
17:30-18:30 Satellite Symposium 2

Changing the trajectory for patients with breast cancer
Satellite Symposium 3

Emerging targeted treatment for rare lung cancer
Satellite Symposium 4

Mapping post-progression treatment options for patients with advanced GC or mCRC
Satellite Symposium 5

Optimal management of BTcP (Breakthrough cancer pain)
Satellite Symposium 6

Navigating a new therapeutic era for Immune-oncology
08:00-08:50 Satellite Symposium 7

Optimizing clinical application of new targeted agents in HCC
Satellite Symposium 8

New indication of immune-check point inhibitor PDL-1 antibody
Satellite Symposium 9

Metastatic cancers and bone health management
Satellite Symposium 10

New Insights and Clinical Implications for the Treatment of ALK+NSCLC
Poster Session
09:00-10:30 Scientific Symposium 8
Partnering between biotechs and investigators in early phase drug development
Scientific Symposium 9
Precision oncology and cancer epigenetics
Joint Symposium

Awareness and Understanding of Toxicities from Immunotherapy
Presentation 4
10:30-10:50 Break
10:50-11:30 Plenary Lecture 2
Past, present and future of geriatric oncology
Hans Wildiers
(University Hospitals Leuven, Belgium)
11:30-12:10 Noe Kyeong Kim Memorial Award & Lecture
12:10-12:50 Luncheon Symposium 3

The new era of advanced NSCLC treatment: Time to navigate patient journey with optimal front-line treatment
Satellite Symposium 11

What is being considered for continuum of care in metastatic colorectal cancer?
12:50-13:10 Break
13:10-13:50 Plenary Lecture 3
The reality versus potential of immune check-point inhibitors as cancer therapeutics
Heather Wakelee
(Stanford University, USA)
13:50-14:00 Break
14:00-15:30 JSMO/KSMO
Joint Symposium

Clinical trials in Asia: opportunities and challenges
Scientific Symposium 10
Geriatric oncology
KSSO/KSMO Joint Symposium
Evolving strategies for surgery and systemic therapy in the neoadjuvant treatment era
Presentation 5
15:30-15:50 Break
15:50-17:20 KSP/KSMO
Joint Symposium

Immune Biomarker
Scientific Symposium 11
Radiomics: Primer for medical oncologists
Oncology Multi-Disciplinary Symposium
Discrepancy between clinical practice and regulation in Korea KOR
Multidisciplinary Oncology Team Education Session 3
CRC/CRA in clinical trial of precision medicine KOR
17:20-17:40 Closing Ceremony